Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GSV
|
|||
| Former ID |
DIB009566
|
|||
| Drug Name |
FBT-A05
|
|||
| Synonyms |
Lymphomun; Bi-20; TPBs-05; Anti-CD20 bivalent monoclonal antibody (hematological cancer), Fresenius Biotech; Trifunctional antibody therapy (blood malignancy), Fresenius/Trion; Anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | |
| Company |
TRION Pharma GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030721) | |||
| REF 2 | Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.